Michaela Mattheus

Boehringer Ingelheim (Germany) — Germany

Medicine · Health Sciences

32h-index19.5kcitations143works27.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(125), Pancreatic function and diabetes(56), Diabetes Management and Research(44), Metabolism, Diabetes, and Cancer(35), Cardiovascular Function and Risk Factors(19)

Publications142 total

Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI
ESC Heart Failure·2025· 1 citedOpen Access
Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction
Nature Cardiovascular Research·2025· 2 citedOpen Access
Empagliflozin in Acute Myocardial Infarction in Patients with and Without Type 2 Diabetes: A Pre-Specified Analysis of the EMPACT-MI Trial
European Journal of Heart Failure·2024· 7 citedOpen Access
BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study
Cardiovascular Diabetology·2024· 9 citedOpen Access
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
Cardiovascular Diabetology·2024· 9 citedOpen Access
Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial
Diabetes Research and Clinical Practice·2024Open Access
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Journal of the American College of Cardiology·2024· 31 citedOpen Access
Empagliflozin after Acute Myocardial Infarction
New England Journal of Medicine·2024· 223 citedOpen Access
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Circulation·2024· 80 citedOpen Access
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium
Therapeutic Innovation & Regulatory Science·2024· 2 citedOpen Access
BMI Variability and Cardiovascular Outcomes Within Clinical Trial and Real-World Environments in Type 2 Diabetes: An IMI2 SOPHIA study
2024Open Access
BMI Variability and Cardiovascular Outcomes Within Clinical Trial and Real-World Environments in Type 2 Diabetes: An IMI2 SOPHIA study
2024Open Access
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
Nephrology Dialysis Transplantation·2024· 41 citedOpen Access
Early Changes in Estimated Glomerular Filtration Rate Post-Initiation of Empagliflozin in EMPEROR-Preserved
European Journal of Heart Failure·2024· 20 citedOpen Access
An Open Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials - Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium
2024Open Access
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin
JAMA Cardiology·2024· 14 citedOpen Access
Kidney and Heart Failure Events are Bidirectionally Associated in Patients with Type 2 Diabetes and Cardiovascular Disease
ESC Heart Failure·2023· 14 citedOpen Access
An Open Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials - Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium
2023Open Access
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
Kidney Medicine·2023· 6 citedOpen Access
An Open Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials - Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium
2023· 1 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Christoph Wanner(27), Bernard Zinman(25), Silvio E. Inzucchi(20), Uli C. Broedl(16), Odd Erik Johansen(13), Jyothis T. George(12), Sreeraj Macha(12), Hans J. Woerle(11), David Fitchett(10), Maximilian von Eynatten(10), Hans J. Woerle(8), Stefan D. Anker(8), Sabine Pinnetti(8), Nikolaus Marx(7), John M. Lachin(6), Julio Rosenstock(6), Mark A. Espeland(6), Audrey Koitka‐Weber(6), Javed Butler(6), Martina Brueckmann(6)